Study of brain GABA signals in Dravet syndrome
Part of Brain & nervous system clinical trials.
This study looks at “GABA signals” in the body/brain to learn more about Dravet syndrome and how it may relate to seizures. If you have Dravet syndrome caused by a specific SCN1A gene change, you may be asked to provide genetic test results and help with study visits so researchers can compare biomarker readings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (a parent/caregiver) must be able to read, understand, and sign consent; if the child can, they must agree (assent).
- The child must be between 0 and 18 years old at the time you sign consent.
- The child must have a confirmed SCN1A genetic test result that is labeled “pathogenic” or “likely pathogenic.”
- Before the first seizure, development should have been normal (no clear developmental problems yet).
- The first seizure should have started between 3 and 5 months of age and match specific seizure types.
- A pediatric neurologist must have diagnosed the child with Dravet syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study aims to better understand SCN1A-related epilepsies by following patients over time. Researchers hope to learn more about how the condition progresses to help develop future treatments.
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
This study tests a new gene therapy called ION337 designed to treat Dravet syndrome, a severe childhood epilepsy caused by a SCN1A gene mutation. The therapy is given as a spinal fluid injection and aims to reduce seizures in children ages 2–12.
This study uses a special PET-MRI scan to look at a brain chemical pathway linked to serotonin (a mood-regulating substance) in people with Dravet syndrome or certain types of epilepsy, and in healthy volunteers. It may help understand how the brain works in these conditions.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
Hear when a new Dravet Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.